Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer

This study investigates whether the combination of perioperative enfortumab vedotin and pembrolizumab improves outcomes in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy compared to surgery alone. The results indicate that the combination therapy significantly enhances event-free survival, overall survival, and the rate of pathological complete response. The findings suggest that this treatment approach may offer a beneficial alternative for this patient population.